[Adjuvant endocrine therapy--Zitazonium--in breast cancer].
The authors deal with the problems of adjuvant therapy of breast cancer. They administrated Zitazonium in those postmenopausal women who had had positive axillary lymph nodes. In the course of analyzing the results, they calculated survival and tumor free survival with "life-table" method, while they used log-rank probe and Mantel-Haenzel X2 probe for showing significance between the diagrams. The results were favourable, but no significant variance could be shown in the group treated with Zitazonium. If lymph nodes were proved to be negative the difference between the graphs were minimal. They refer to the question of steroid receptor determination and emphasize to take into account the biological markers when projecting adjuvant therapy.
Márkus
B
B
Altalános Sebészeti Osztály, Vas megyei Markusovszky Kórház--Szombathely.
Kántor
E
E
Pintér
G
G
Brittig
F
F
Padányi
J
J
Kocsis
E
E
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015415:Biomarkers; D014408:Biomarkers, Tumor; D001943:Breast Neoplasms / Q000188:drug therapy / Q000601:surgery*; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008593:Menopause; D008875:Middle Aged; D013629:Tamoxifen / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D015415:Biomarkers; D014408:Biomarkers, Tumor; D013629:Tamoxifen